Back to search
FDAFDA · Food and drugs·Recall number D-0357-2026

Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054, NDC: 45963-678-11

Published March 11, 2026 · Recall initiated: January 29, 2026

Summary

FDA records drug Class II recall D-0357-2026, published March 11, 2026 and initiated January 29, 2026. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Ongoing; Reported quantity: 19,056 bottles; Lot: Lot#: a) 0686H251, 0687H251, 10688H251, Exp.: 02/2027. . Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA, Inc
Distributor
Nationwide
Lot
Lot#: a) 0686H251, 0687H251, 10688H251, Exp.: 02/2027. .
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054, NDC: 45963-678-11 recalled?

Yes. FDA published recall D-0357-2026 on March 11, 2026. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter